华北制药：子公司获得重组破伤风疫苗（大肠埃希菌）临床试验批准通知书

Core Viewpoint - Huabei Pharmaceutical (600812.SH) announced that its subsidiary, Huabei Pharmaceutical Jintan Biotechnology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of a recombinant tetanus vaccine, marking a significant advancement in vaccine development in China [1] Group 1: Company Developments - The recombinant tetanus vaccine is a new generation vaccine that has shown good safety, immunogenicity, and protective effects in animal studies [1] - Currently, there are no gene-engineered recombinant tetanus vaccines available in the domestic or international market, with only one other company in China at the phase I clinical trial stage [1]